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ABSTRACT
Objectives: Platelet-derived growth factor B (PDGF-B) and nestin have been suggested to be useful in the assessment of 
neoangiogenesis in malignant ovarian masses. We aimed to investigate a possible association of these markers with newly 
formed microcapillaries and perivascular cells in ovarian tumors. 
Material and methods: Microvessel density (MVD) and pericytes were studied in 82 women with ovarian neoplasms, 
including 7 benign cysts, 7 borderline masses, 64 epithelial ovarian cancers and 4 other malignant ovarian tumors. Im-
munohistochemical staining included antibodies to CD34, PDGF-B and nestin. 
Results: Median values of CD34-positive and nestin-positive MVD were: 24,5 (range:17-32) and 21 (range: 12–31), respec-
tively. No significant correlation between intratumoral CD-34 positive MVD and nestin-positive MVD was found. Benign 
and borderline lesions more frequently than malignant tumors displayed low or medium values of nestin-positive MVD 
(p = 0.01). Histological grading of malignant tumors was associated with nestin-positive MVD (p = 0.01). Nestin expression in 
tumor cells was not correlated with tumor grade or histological subtype. PDGF-B expression was found in tumor microves-
sels in 72% of cases (59/82). High expression of PDGF in pericapillary cells was strongly associated with high expression of 
this marker in cancer cells (p = 0.007). Significant correlations between PDGF-B and nestin expression in malignant tumor 
microvessels were also found (p = 0.04). Nestin and PDGF-B expressions were strongly associated with high grade tumors 
when compared to low grade or benign masses. 
Conclusions: We conclude that the assessment of PDGF-B and nestin-positive MVD could be used to identify only highly 
active, angiogenic malignant ovarian masses, where tumor vasculature is formed. 
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INTRODUCTION
Epithelial ovarian cancer (EOC) remains the most le-
thal gynecological malignancy, mainly because of late 
detection and rapid metastasis formation. Conventional 
therapies include various taxan/platinum based regimens 
of chemotherapy and, more recently, targeted therapies 
such as antivascular therapy. However, the majority of 
women with advanced disease will delvelop recurrence 
within 2 years of the initial surgical treatment. Most solid 
malignant tumors require angiogenesis for their growth 
beyond 2–3 mm in size [1]. Formation of microvasculature 
is also an essential step that allows tumor cells to enter 
systemic circulation of the host organism. Novel antian-
giogenic cancer regimens require new studies to better 
understand the features of intratumoral vessels. One of the 
most important issues includes generation and maturation 
of a tumor microvascular network. Several recent studies 
have shown that cancer microvessels are characterized not 
only by abnormal pericyte coverage, but also by disturbed 
interactions between pericytes and endothelial cells, both 
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of which may contribute to the metastasic dissemination 
of various cancers [2, 3]. 
Tumor microvessels in various human cancers are struc-
turally and functionally abnormal [3, 4]. One of the impor-
tant features of the newly formed tumor microvessels is their 
increased permeability to electrolytes and proteins due to 
different structure of the basement membrane. This feature 
enables malignant tumor cells to penetrate the barrier more 
easily than through the mature microvessels [4, 5]. Increased 
tumor microvessel density (MVD) could be used as a pre-
dictive indicator of poor survival in various types of cancer 
patients. In the last two decades MVD in various cancers has 
been widely studied with the use of immunohistochemistry. 
Vascular endothelial cells of normal tissues were commonly 
stained with panendothelial cells markers such as CD34, 
CD31 or factor VIII associated antigen, one of the essential 
blood clotting proteins [6]. However, these markers can-
not specifically identify newly formed tumor capillaries, 
moreover, they usually also detect pre-existing, relatively 
large sized blood vessels. Because of these features, the 
above markers are currently not considered suitable for 
the sensitive analysis of tumor neoangiogenesis. Potential 
clinical significance of MVD analysis in women with EOC 
remains controversial [7]. In contrast to a variety of solid 
neoplasms, MVD does not seem to be a useful predictor 
of survival in patients with EOC. Several reasons seem to 
be responsible with the most important one, the hetero-
genic nature of microvascular network in ovarian cancer 
patients. Great variety of newly formed and preexisting 
blood vessels makes panendothelial markers like CD34 or 
CD31 not specific enough to show prognostic significance 
when tested in multivariate analysis [7]. 
One of the novel markers of the proliferating endothelio-
cytes is nestin — an intermediate filament protein, initially 
thought to be exclusively associated with neuro-progenitor 
cells [8–10]. Although nestin is expressed during early stages 
of normal cells development, under pathological conditions 
this protein could be also found in cancer stem cells, as well 
as in perivascular and endothelial cells suggesting its role 
in various malignant tumors neoangiogenesis [11, 12]. In 
recent years, an increased nestin expression has been re-
ported in multiple malignant masses including CNS tumors, 
gastrointestinal stromal tumors, pancreatic cancer, prostate 
cancer, breast cancer, malignant melanomas, and thyroid 
tumors [13–15]. High expression of nestin correlated with 
aggressive growth, metastasis, and poor prognosis in these 
cancers. Despite extensive research published to date, not 
all the roles of nestin in malignant tumors growth have 
been well characterized. Recently, it has been suggested 
that nestin could serve as a novel marker of pericytes and 
pericyte-like mural cells and thus of vascular maturation. Re-
modeling of blood vessels network requires tissue-resident 
nestin-positive progenitor cells that represent the basic 
source for pericytes and smooth muscle cells. The assess-
ment of nestin expression as a potential marker for mural 
pericytes was suggested to determine the mechanisms of 
pericytes recruitment and differentiation [13]. Pericytes are 
not only found close to endothelial cells, but can be searched 
by their localiztion to the abluminal side of the blood ves-
sel wall in combination with the expression of various  cell 
surface markers such as α-smooth muscle actin (α-SMA), 
CD146, neural glial 2 (NG2 and/or leptin receptor (LepR). 
Another new potential marker could be platelet-derived 
growth factor (PDGF) as both PDGF and its receptor-beta 
(PDGFRβ) are highly expressed in pericytes [16]. Suppression 
of the PDGF signaling pathway leads not only to pericyte 
loss, but also to endothelial changes followed by capillary 
dilation, microaneurysm formation and rupture [17, 18]. 
Emerging evidence suggests that the PDGF system may 
play an important role in carcinogenesis and because of 
this several new biological agents targeting PDGF signaling 
pathway are currently investigated [19].
Although several studies have investigated nestin and 
PDGF expression in ovarian cancer, little is known about the 
role of these markers in a process of microvessel maturation 
in tumor tissues. The mechanisms responsible for pericytes 
recruitment, migration and regulation of tumor angiogen-
esis in ovarian cancer have not been fully understood. In this 
study we aimed to investigate the possible role of nestin as 
a marker of pericytes in vascular remodeling processes dur-
ing tumor progression. We also aimed to determine possible 
associations between the microvessel count, expression of 
nestin and PDGF-B, and selected clinicopathological fea-
tures in ovarian benign and malignant tumors. 
MATERIAL AND METHODS
Primary human ovarian tumors and nonmalignant tis-
sues were obtained from 82 women with ovarian masses 
who had surgery at the 1st Department of Gynecologi-
cal Oncology and Gynecology of the Medical University 
of Lublin between years 2009–2011. The study has been 
approved by the local Bioethical Committee and all par-
ticipants gave their informed consent. The median age of 
patients was 50 years (range: 18–86 years). Among them 
there were 31 premenopausal (37.8%) women, whereas 
51 were postmenopausal (62.2%). All specimens used in 
this study were examined and selected by an experienced 
pathologist to confirm the diagnosis of either benign or 
malignant ovarian tumors. Excluding benign masses, the 
proportion of malignant cells in tumor tissues was always 
more than 50%. The histological type and grade of malig-
nant tumors were classified according to the criteria of the 
World Health Organization (WHO). The stage of each cancer 
was established according to the International Federation 
122
Ginekologia Polska 2017, vol. 88, no. 3
www. journals.viamedica.pl/ginekologia_polska
of Gynecology and Obstetrics criteria. Final histological 
examination revealed 7 benign lesions (3 fibrothecomas, 
3 ovarian strumas, 1 teratoma), 7 borderline tumors and 
64 primary EOC’s. In addition, the study included 4 other 
malignant ovarian tumors (3 granulosa cell tumors and 
1 malignant Brenner tumor). The most common type of 
EOC was serous cancer (29 women), followed by the en-
dometrioid cancer (19 cases). Table 1 shows selected de-
mographic data and histological diagnosis of the studied 
group. Most malignant tumors were histological grade 
G2 (26 cases) or G3 (34 cases) and 55% (46 cases) were 
FIGO stage III/IV. We also used 10 nonmalignant tissue 
samples from patients who had bilateral oophorectomies 
for suspected malignancy, but were found to have benign 
histology. These samples were collected from apparently 
normal contralateral ovaries and were used as controls for 
immunohistochemical studies. 
Immunohistochemical studies
Immunohistochemical analysis was performed in the 
paraffin wax-embedded representative tumor tissue sec-
tions fixed in 10% neutral buffered formalin. Four-micro- 
meter sections from formalin-fixed, paraffin-embedded tissue 
were mounted on silanized slides (DAKO Cytomation, Den-
mark). The slides were air-dried and the tissue deparaffinized 
and rehydrated. 
The following antibodies and dilutions were used: 
CD34 (mouse, monoclonal IgG Class II, DAKO Cytomation; 
1:50), nestin (mouse, monoclonal IgG 10c2, Santa Cruz 
Biotechnology 1:200) and PDGF-B (mouse monoclonal 
IgG2b F-3; Santa Cruz Biotechnology 1:200) Following de-
parafinization, rehydratation and antigen retrieval with the 
Target Retrieval Solution (Dako Cytomation, Denmark) at 
pH = 6.0 three cycles of heating in a microwave oven (each 
of 5 min, at 750 W) were performed. Tissue sections were 
incubated with the primary antibody for 1 hour in room 
temperature. The slides were incubated with the secondary 
antibody conjugated with streptavidin-biotin-peroxidase 
complex (rabbit/mouse EnVision kit; DAKO Cytomation) 
and color reaction was developed using DAB (3’-3-diami-
nobenzidine tetrahydrochloride, DAKO) according to the 
manufacturer’s protocol. The sections were counterstained 
with Mayer’s hematoxylin. For each case, negative control 
was applied by replacing the antibody by PBS or nonim-
mune serum.
The average number of microvessels within selected tu-
mor areas was assessed  according to Weidner’s method [6]. 
As recommended, sections were first examined at low mag-
nifications (40× and 100×) to identify the most vascular areas 
of the tumors, so called 'hotspots', i.e. the area(s) with most 
intense CD34 or nestin staining and apparently the high-
est density of microvessels. Then, as a rule, 10 fields were 
examined, except in a few cases where less tumor tissue was 
available. The counts were expressed as the average of all 
fields examined at high magnification (200×; HPF — high 
power field) with MVD defined as the mean of number of 
vessels/HPF). PDGF-B and nestin expression in tumor cells 
was assessed semi-quantitatively where both the intensity 
and percentage of stain-positive cells were measured. At 
least 10 microscopic fields in one representative tumor sec-
tion were counted under 400× magnification. The intensity 
of staining was graded '0' for absent staining, '1' for weak, 
'2' for moderate, and '3' for intense immunoreactivity. The 
percentage of stain-positive cells was visually evaluated and 
cell expression was stratified as follows: low; for < 30% posi-
tive cells (weak or absent staining reaction), high > 30% of 
positive cells (moderate or strong staining reaction). Expres-
sion of PDGF-B in microvessels was described as negative 
(lack or weak staining reaction in microvessels) or positive 
(moderate or strong staining reaction).
Table 1. Menopausal status of the studied women and tumor 
characteristics including histological diagnosis. grade and clinical 
Federation of Gynecology and Obstetrics (FIGO staging)
Studied group (n = 82) No. of patients (%)
Type of lesions
Benign ovarian tumors 7 8.3
Borderline tumors 7 8.3
Epithelial ovarian cancer 64 78.5
Other malignant ovarian tumors 4 4.7
Menopausal status
Before menopause 31 37.8
After menopause 51 62.2
Histological grade
1 15 18.2
2 26 31.7
3 34 41.4
FIGO stage
I 24 29.2
II 6 7.3
III 42 51.2
IV 3 3.6
Histological subtype
Serous 29 35.3
Endometrioid 19 23.1
Mucinous 11 13.4
Metastatic 5 6.1
undifferentiated 4 4.8
Anaplastic 2 2.4
Germinal 1 1.2
Clear cell 1 1.2
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Statistical analysis
Statistical analysis was performed with the use of 
Statistica v. 10.0 (Statsoft, Poland). Association between 
categorical variables was examined by Pearson’s χ2 test 
or Fisher’s exact tests, where appropriate. Mann-Whitney 
nonparametric test was used to compare categorical with 
continuous tumor variables when there were two catego-
ries, whereas Kruskal-Wallis nonparametric test was used 
instead, when there were more than two categories. The 
criterion of statistical significance applied in all calculations 
was p < 0.05. 
RESULTS
Ovarian tumor vasculature assessment  
with CD34 antibody 
Median CD34-positive microvessel density assessed 
in studied ovarian tumors was 24 (range: 5–56) per high 
power field. No significant differences in MVD-CD34 were 
found in benign, borderline and invasive tumors subgroups 
(p = 0.73). Histological grading and FIGO stage were not 
correlated with MVD-CD34 (p = 0.4 and p = 0.09, respec-
tively). Significant differences in microvessel density be-
tween histological subgroups of malignant tumors were 
found (p = 0.04). The highest MVD-CD34 was observed 
in mucinous tumor type (MD = 34) and in non-EOC ma-
lignant tumors (MD = 39). In serous and endometrioid 
tumor types calculated median MVD-CD34 was 24/HPF. 
The lowest microvessel density was observed in metastatic 
(MD = 14), germinal (MD = 13) and clear cell (MD = 6) tumor 
types. Figure 1 shows typical example of CD34 staining in 
tumor microcapillaries.
Nestin expression in tumor and perivascular cells
Immunohistochemical staining revealed nestin pres-
ence in the cytoplasm of neoplastic cells and in mural cells 
of microcapilaries in 80 cases (97.5%) of ovarian tumors. The 
Figure 1. Example of CD34 staining in endothelial cells 
around tumor microvessels in ovarian serous carcinoma G3. 
Magnification 200×
Figure 2. Example of high nestin expression in tumor cells in 
endometrioid cystadenocarcinoma G3. Magnification 100×
Figure 3. Example of low nestin expression in tumor cells. 
 Staining reaction is predominantly localized in cytoplasm  
of endothelial cells around small microcapillaries (selected 
area is presented on Fig. 4). Magnification 100×
Figure 4. Nestin staining in the same sample, nestin protein is 
predominantly localized in the cytoplasm of endothelial cells 
in small microcapillaries (red arrows). Magnification 400× 
examples of nestin staining reaction are shown on Fig-
ures 2–4. The results of nestin expression assessment in tu-
mor cells, nestin-positive microvessel density (MVD-nestin) 
and their relationship with clinicopathological features are 
presented in Table 2. Most of the benign or borderline type 
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of lesions displayed only week staining reaction in tumor 
cells. High nestin expression was found in 28 (34%) cases, 
which included mainly women with ovarian cancer, however 
the differences between the groups were not statistically 
significant. Histological grade and FIGO stage of malignant 
tumors were not correlated with nestin expression in tumor 
cells. No significant differences in nestin expression by tu-
mor cells according to ovarian cancer histological subtype 
were found.
Median density of nestin-positive microvessels in the 
studied tumors was 21 (range: 12–31). In women with EOC 
median nestin-positive MVD was MD = 21/HPF (range: 
14–29). The highest median MVD-nestin was observed in 
malignant non-EOC subgroup (42/HPF; range 37–48). The 
lowest MVD-nestin was found in benign and borderline 
tumors (12/HPF; range 7–21 and 18/HPF; range 11–21, re-
spectively). The differences between these groups were 
statistically significant (p = 0.01). Clinical advanced tumors 
(FIGO III and IV) significantly more frequently displayed 
higher nestin-positive MVD than low FIGO stage tumors 
(24/HPF; range 15–35 vs. 15 /HPF; range 11–24, respec-
tively, p = 0.04). There were no significant differences in 
median nestin-positive MVD according to histological sub-
type and histopathological grade of malignant tumors. Ex-
pression of nestin in tumor cells was not associated with 
MVD-nestin (p > 0.05). In lesions with low expression pattern 
median values of nestin-positive MVD was slightly higher 
than in samples where staining reaction was moderate or 
high (22/HPF; range 13–37 vs. 19/HPF; range 12–20). No sig-
nificant correlation between MVD-CD34 and nestin-positive 
MVD (r = 0.14; p = 0.19) was found. 
Platelet derived growth factor (PDGF-B) 
expression in neoplastic cells  
and microcapillaries
PDGF-B antibody staining was found both in cytoplasm 
of neoplastic cells and in pericapillary cells (Figs. 5 and 6). No 
PDGF-B staining was observed in 5 cases of ovarian tumors 
and high expression was found in 27 (33%) cases. Benign le-
sions more frequently were characterized with weak or lack 
of the PDGF-B expression in tumor cells (6 of 7 cases, 86%) 
and EOC samples displayed more often high staining pat-
tern in tumor cells (45 of 64 cases; 70%). The differences 
between various types of lesions were statistically significant 
(p = 0.01). No significant differences were found between 
tumor histological type or FIGO stage when PDGF-B ex-
Table 2. Relationship between nestin expression in tumor cells, nestin-positive microvessel density (MVD-nestin) and clinicopathological features
No. of patients
Nestin expression in tumor cells Microvessel density nestin-positive
Negative 
(n = 54)
Positive
(n = 28) P value Median (range) P value
Type of lesion
Benign ovarian tumor, n = 7 5 (72%) 2 (28%)
0.9
18.5 (11–21)
0.01
Borderline tumor, n = 7 5 (72) 2 (28%) 12 (7–21)
Ovarian cancer, n = 64 42 (66%) 22 (34%) 21 (14–29)
Malignant tumor, n = 4 2 (50%) 2 (50%) 41 (37–48)
Histological grading
G1, n = 15 10 (67%) 5 (33%)
0.9
12 (7–22)
0.14G2, n = 26 16 (62%) 10 (38%) 22 (14–30)
G3, n = 34 23 (68%) 11 (32%) 21 (14–32
FIGO stage
I + II, n = 30 21 (70%) 9 (30%)
0.4
15 (11–24)
0.04
II + IV, n = 45 28 (62%) 17 (38%) 24 (15–35)
FIGO — Federation of Gynecology and Obstetrics
Figure 5. Example of PDGF-B staining in serous adenocarcinoma G2 
(selected area is presented on Fig. 6). Magnification 100×
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pression was found in tumor cells (p  >  0.5). Histological 
subtype of invasive tumors had no significant association 
with PDGF-B expression in tumor cells (p > 0.5). The results 
of PDGF expression assessment are shown in Table 3.
PDGF-B expression was found in tumor microvessels in 
72% of cases (59 of 82). High expression of PDGF in pericapil-
lary cells was strongly associated with high expression of this 
marker in neoplastic cells (p = 0.007). The expression pattern 
of PDGF-B was significantly different according to the type 
of lesion (p = 0.03). We have noticed that most of the benign 
(5 of 7 samples, 71%) and all borderline tumor revealed lack 
or low expression pattern of PDGF-B in microcapillaries. Sig-
nificant differences in PDGF-B expression in microcapillar-
ies were correlated with histological grade of the invasive 
malignant tumors (p = 0.03). Low grade (G1) tumors more 
often displayed low staining pattern of PDGF-B in microves-
sels (11 of 15 cases, 73%). As shown in Table 4 histological 
subtype or clinical stage of invasive tumors did not affect the 
PDGF-B expression in perivascular cells (p>0.05). Strong as-
sociations between PDGF-B expression in tumor cells and in 
perivascular cells with MVD-nestin ( both p = 0.0003), but not 
with MVD-CD34 (p > 0.05) were found.  In women with can-
cers that had low expression pattern of tumor cells PDGF-B, 
median MVD-nestin was significantly lower than in tumors 
were the PDGF-B staining reaction was strong (16/HPF; 
range 7–21vs. 22/HPF; range 14–36, respectively). Similar Figure 6. PDGF-B staining in serous adenocarcinoma. As shown, 
PDGF-B is localized in tumor cells and in cell around microvessels 
(probably pericytes/mural cells); red arrows point to microcapillaries 
with erythrocytes inside. Magnification 400×
Table 3. Relationships between platelet-derived growth factor (PDGF) expression and clinicopathological features
No. of patients
PDGF expression
In microvessels In tumor cell
Low 
(n = 47)
High
(n = 35) P value
Low
(n = 28)
High
(n = 54) P value
Type of lesion
Benign tumors, n = 7 5 (71%) 2 (29%)
0.03
6 (86%)
3 (43%)
19 (30%)
0 (0%)
1 (14%)
0.01
Borderline tumors, n = 7 7 (100%) 0 (0%) 4 (57%)
Ovarian cancer, n = 64 33 (52%) 31 (48%) 45 (70%)
Other malignant tumors, n = 4 2 (50%) 2 (50%) 4 (100%)
Histological grading
G1, n = 15 11 (73%) 4 (27%)
0.03
6 (40%)
8 (30%)
8 (24%)
9 (60%)
0.5G2, n = 26 9 (36%) 17 (66%) 18 (70%)
G3, n = 34 20 (59%) 14 (41%) 26 (76%)
FIGO stage
I + II, n = 30 19 (53%) 21 (47%)
0.15 11 (37%)19 (63%)
11 (24%)
0.25
II + IV, n = 45 21 (47%) 24 (53%) 34 (76%)
FIGO — Federation of Gynecology and Obstetrics 
Table 4. Statistical comparison of differences in microvessel 
density for CD34-positive vs. nestin-positive groups according to 
clinicopathological and histological features (p-value: Kruskal-
Wallis test)
MVD-CD34+ MVD-nestin+
Type of lesion 0.7 0.01
Histological subtype 0.04 0.3
Histological grading 0.4 0.1
FIGO stage 0.09 0.2
PDGF expression in tumor cell 0.9 0.0003
PDGF expression in microvessels 0.24 0.0003
Nestin expression in tumor cells 0.09 0.2
FIGO — Federation of Gynecology and Obstetrics; PDGF — platelet-derived 
growth factor
126
Ginekologia Polska 2017, vol. 88, no. 3
www. journals.viamedica.pl/ginekologia_polska
differences in MVD-nestin were found in tumors with low 
and high expression pattern PDGF-B in perivascular cells 
(17/HPF; range 10–22 vs. 25/HPF; range 15–38 respectively).
DISCUSSION
Most women with advanced ovarian cancer although 
usually sensitive to the primary chemotherapy will relapse 
within next few years. An improvement of the treatment 
outcome may be based on a higher number of the indi-
vidualized therapies that will be based on the new, clini-
cally validated predictive and prognostic markers including 
novel tumor angiogenesis factors. Neoangiogenesis in ma-
lignant tumors requires both endothelial cell proliferation 
and pericytes activation for the stabilization of microvessel 
sprouts. In our study we have attempted to determine the 
linkage between nestin, PDGF and degree of maturation of 
tumor vasculature in benign and malignant ovarian neo-
plasms. Our results confirmed previously reported obser-
vations that nestin is frequently expressed in malignant 
ovarian tumors [14]. Strong staining pattern of nestin was 
observed both in tumor cells and in mural cells of tumor 
microcapillaries. We have also found that nestin expression 
in tumor microvessels, but not in cancer cells increased with 
tumor grade and clinical stage of the disease. The lowest me-
dians of nestin positive microvessels were found in benign 
and borderline ovarian tumors. Clinically advanced cancers 
more frequently displayed higher median MVD-nestin posi-
tive microvessels than low FIGO stage tumors. 
Nestin has been reported to correlate with aggressive 
growth, metastasis, and poor prognosis in several ma-
lignancies; however, the role of nestin in ovarian cancer 
neoangiogenesis has not been well characterized [8, 11, 
14, 15]. Compared to MVD studies that used several pan-
endothelial markers, only a limited number of investiga-
tions have employed nestin. Nestin could serve not only as 
a reliable neovascularization marker but also may reflect 
cancer stem cell properties in different types of malignant 
masses, correlating with poor prognosis. Osman et al. [20] 
found the expression of nestin in almost 50% of all epi-
thelial ovarian cancers and this neurofilament protein was 
expressed more often (60%) in serous type of tumors. In 
our study nestin expression pattern in microvessels did 
not correlate with nestin expression in tumor cells. Also, no 
association between MVD-nestin positive microvessels and 
MVD-CD34 stained microvessels was found. Interestingly, 
nestin-positive cells were identificated in the newly formed 
blood vessels suggesting that these cells might have been 
derived from nestin-positive  tissue-resident multipotent 
stem cells. In contrast, mature vessels were either negative or 
only slightly positive for nestin immunostaining and mainly 
dispalyed CD34-positive staining pattern. Interestingly, we 
have found that tumors with lower number of CD34-positive 
microvessels more often were expressing a higher number 
of nestin-positive microvessels. Conversely, higher density 
of CD34-positive microvessels was observed in tumors with 
lower counts of nestin-positive MVD. This observation con-
firms that nestin could be a more appropriate marker to 
identify only highly angiogenic malignant ovarian lesions 
where tumor vasculature is actively formed.
The origin of nestin-positive vascular endothelial cells in 
tumor tissue is still controversial. As a possible mechanism, 
a migration of mesenchymal stem cells from the bone mar-
row has been proposed by Dong et al. who showed that 
human glioma stem/progenitor cells transdifferentiate into 
vascular endothelial cells in vitro and in vivo [21]. Although 
it is still not known whether nestin expression is restricted 
to angiogenic endothelial cells or to nestin expressing stem 
cells that are recruited to the newly formed blood vessels, 
our results are in line with the hypothesis that nestin could 
be included as a novel marker of neoangiogenesis and 
vascular remodeling proceses in ovarian cancer. 
The mechanisms responsible for pericytes recruitment, 
migration and regulation of tumor angiogenesis have not 
been fully understood. PDGF may trigger microvessel for-
mation by priming vascular smooth muscle cells and/or 
pericytes to release pro-angiogenic factors. Emerging evi-
dence suggests that the PDGF system plays an essential role 
in ovarian cancer progression [22]. Still, there are only few 
published studies on PDGF-B expression in ovarian malig-
nancies [23, 24]. Our results confirmed that in women with 
ovarian cancer the sources of PDGF-B could be both tumor 
cells and endothelial cell/pericytes. We have found that 
expression of PDGF-B increased with the aggressiveness 
of tumors as assessed by tumor histological grade. Benign 
or borderline lesions more frequently had low expression 
of PDGF-B, whereas high grade and FIGO advanced stage 
types of ovarian cancer displayed more often strong staining 
pattern of this marker both in cancer cells and in microves-
sels. Our results are in agreement with previous findings 
that during vascular formation activated endothelial cells or 
tumor cells can secrete PDGF-B and paracrine stimulation of 
PDGF receptor (PDGF-R) promotes pericyte precursor cell to 
proliferation and migration [25]. We have found that a high 
ratio of PDGF-B expression in microvessels is correlated 
with higher density of nestin-positive microvessels but not 
with CD34-positive MVD. Only few reports have focused on 
PDGF isoforms or their receptors expression in women with 
ovarian cancer and to date, the role of the PDGF-B signaling 
pathway has not yet been explained. 
Madsen et al. [23] demonstrated the presence of target 
for both PDGFR-α and PDGFR-β in the tumor and stromal 
compartments of a substantial proportion of the ovarian can-
cer samples. They found high PDGFR-β expression in tumor 
cells in 60% of clear cell adenocarcinomas, but no expression 
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of PDGFR-α. However, in stromal cells 40% of their cases 
stained positive for PDGFR-α. In another study from the same 
group Madsen et al. [24] have measured serum PDGF-AA, 
PDGF-BB, FGF2, and VEGF concentrations in bevacizumab 
treated multiresistant ovarian cancer patients. The levels of 
these cytokines were up-regulated in ovarian cancer and were 
associated with stage and residual disease. More recently, 
Hosaka et al. [25] have demostrated that PDGF-B induces 
pericyte-fibroblast transition (PFT), which was significantly 
correlated with tumor invasion properties. Moreover, they 
also demontrated that the coimplantation of PFT cells with 
less-invasive tumor cells in mice markedly promoted tumor 
dissemination and invasion, leading to an increased number 
of circulating tumor cells and metastasis [25]. 
Tumor vessels are stabilized by the integration of smooth 
muscle cells and pericytes. Such maturation and stabiliza-
tion of the new microvessels is thought to be responsible 
for their resistance to the drugs used in the antivascular 
tumor therapy [13]. Therefore, new treatment modalities are 
urgently needed. Targeting multiple angiogenic signaling 
pathways by various molecular agents including tyrosine 
kinase inhibitors is a promising strategy to modulate tumor 
vascularization, microcirculation, and effectively block the 
growth of angiogenesis-dependent tumors. Additionally, 
pericyte-targeting seems to be an effective supporting an-
ticancer therapy. Recently, Lu et al. [26] tested the efficacy of 
a highly selective aptamer (AX102) against PDGF-B with or 
without anti-VEGF therapy (bevacizumab) in ovarian cancer 
models in vitro. They found that combination of two agents 
for endothelial (bevacizumab) and pericyte (AX102) targets 
significantly reduced MVD, vascular maturation as assessed 
by pericyte coverage fraction and proliferation index (PCNA) 
in their treatment group. In summary, our results dem-
onstrate the importance of nestin and PDGF signaling in 
promoting vascular growth, vessel maturation and vascular 
remodeling in malignant ovarian tumors.
CONCLUSIONS
1. Nestin as a novel marker for mural pericytes could be used 
to better characterize the mechanisms of pericytes recruit-
ment and differentiation and their relationship to clinical 
outcome in women with malignant ovarian tumors.
2. Ovarian cancers should be checked for alternative an-
giogenic pathways to look for possible new multidrug 
antiangiogenic treatment stategies.
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